New targeted drug trial offers hope for Tough-to-Treat breast cancer
NCT ID NCT06224673
Summary
This study is testing whether a new drug called ARX788 can help control advanced breast cancer that has a specific low level of a protein called HER2. The drug is given by IV infusion and works by attaching a cancer-killing toxin directly to tumor cells. Researchers will enroll 36 adults whose cancer has progressed after prior treatment to see if the therapy shrinks tumors and is safe, while also testing eye drops to prevent potential side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.